Depression

by David Wimbish
The dull ache of depression had lodged in my belly for several years like a sponge, soaking away the dopamine and serotonin from the rest of my body, buoyed only by, “it runs in the family,” from a generation that thought therapy, and especially medication, meant institutionalization and perhaps an eventual lobotomy.  
by Tim and Mike Bernard
My father and I wrote IT SOUNDED BETTER IN MY HEAD — a fictional account of my mental health journey and my personal growth through music.  In a country, where it seems the majority of our youth are silently struggling with mental health, I think our story will resonate for a wide population as we all suffer together.
It can be difficult to talk about suicide. It’s a taboo topic, fraught with discomfort. Couple that with some harmful misunderstandings and our tendency, as a society, to shy away from hard conversations, and it’s no wonder that you may struggle to find the right words.  
When a person seeks information about treatment for themselves or their loved one, the importance of connecting them with the appropriate level of care right from the start cannot be overstated.

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Eligibility Criteria

•    Adults 18 to 65 years, inclusive.
•    Meets DSM-5 criteria for major depressive disorder.
•    Currently experiencing a major depressive episode.
•    Has had an inadequate response to current ongoing treatment with an approved antidepressant.
 

Exclusion Criteria
  • Treatment-resistant depression.
  • History of bipolar I or II disorder.
  • Any psychiatric condition which takes a primary focus of treatment over MDD.
  • Significant or poorly controlled concomitant medical illness.
  • Alcohol or other substance use disorder.
  • Pregnant, breast-feeding or planning to become pregnant or breast-feed during the study.
  • Significant risk of suicide.
State
Alabama
California
Connecticut
Florida
Georgia
Idaho
Maryland
Nevada
New Jersey
New York
Ohio
Pennsylvania
Texas

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.

IRB approval #: 20210876

by Jessica Wendi Abel
When I was 9-months pregnant with my second baby, I tried to find a children’s picture book to read with my nearly five-year-old about a family living with the most common condition after childbirth—postpartum depression—and was shocked to find no book like this in 2020. I set out to create a resource for the 1 in 7 women who will experience postpartum depression along with their families. 
by Gordon Fraser
“As traumatized children, we always dreamed that someone would come and save us. We never dreamed that it would, in fact, be ourselves as adults.” – Alice Little 
by Daneisha Carter
My name is Daneisha and I'm an African American woman who suffers from severe anxiety and stress. I was around 18 years old when I had my first panic attack. I couldn't breathe and it felt like I was going to die.
by Carmen M. Tumialan Lynas, PhD
Most would agree that treating invasive cancer when it is still just the size of a mustard seed has a much better prognosis than waiting and treating it when it metastasizes into a larger, less curable disease. My cancer experience makes me more resolute about treating anxiety early. 
by Brandon Karasinski (AESTHETIC))
For many years music helped me to feel less alone going through something I hadn’t come to understand about myself until recently. My new song CARE describes that fork in the road we all come across in our lives where we have two paths to choose walking down.